Qi Ling1, Xiao Xu, Qiang Wei, Xuyong Wei, Zhuoyi Wang, Lin Zhou, Shusen Zheng. 1. Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, 79 QingChun Road, HangZhou, China.
Abstract
BACKGROUND: Preexisting diabetes mellitus (DM) has been reported to have an adverse consequence on patient prognosis after liver transplantation in the West. So far, there are few reports on the effect of preexisting DM on outcome of liver transplant recipients with HBV infection. AIMS: We aimed to examine the impact of preexisting DM on post-transplant outcome in Chinese patients with HBV-related liver disease. METHODS: The post-transplant morbidities and patient survival were compared between 48 diabetes patients (DM group) and 96 non-diabetes patients (control group) matched for age, gender, primary disease and model for end-stage liver diseases score. The DM group was further divided into hyperglycemia patients (fasting blood glucose >8.0 mmol/L, n = 22) and non-hyperglycemia patients (fasting blood glucose ≤8.0 mmol/L, n = 26). RESULTS: Patient characteristics were comparable between both groups, except a higher incidence of hepatic encephalopathy in the DM group than that in the control group (22.9% vs. 10.4%, P = 0.045). The incidences of post-transplant complications and patient survival did not differ significantly between the DM and control groups, or between non-hyperglycemia patients and their matched case controls. Hyperglycemia patients showed a higher incidence of post-transplant sepsis (18.2% vs. 2.3%, P = 0.039) and biliary complications (31.8% vs. 6.8%, P = 0.012) than their matched case controls. CONCLUSIONS: Preexisting DM is not a contraindication for liver transplantation in patients with HBV-related liver disease. A tight control of blood glucose to a level of ≤8.0 mmol/L was necessary to reduce the risk of complications after liver transplantation.
BACKGROUND: Preexisting diabetes mellitus (DM) has been reported to have an adverse consequence on patient prognosis after liver transplantation in the West. So far, there are few reports on the effect of preexisting DM on outcome of liver transplant recipients with HBV infection. AIMS: We aimed to examine the impact of preexisting DM on post-transplant outcome in Chinese patients with HBV-related liver disease. METHODS: The post-transplant morbidities and patient survival were compared between 48 diabetespatients (DM group) and 96 non-diabetespatients (control group) matched for age, gender, primary disease and model for end-stage liver diseases score. The DM group was further divided into hyperglycemiapatients (fasting blood glucose >8.0 mmol/L, n = 22) and non-hyperglycemiapatients (fasting blood glucose ≤8.0 mmol/L, n = 26). RESULTS:Patient characteristics were comparable between both groups, except a higher incidence of hepatic encephalopathy in the DM group than that in the control group (22.9% vs. 10.4%, P = 0.045). The incidences of post-transplant complications and patient survival did not differ significantly between the DM and control groups, or between non-hyperglycemiapatients and their matched case controls. Hyperglycemiapatients showed a higher incidence of post-transplant sepsis (18.2% vs. 2.3%, P = 0.039) and biliary complications (31.8% vs. 6.8%, P = 0.012) than their matched case controls. CONCLUSIONS: Preexisting DM is not a contraindication for liver transplantation in patients with HBV-related liver disease. A tight control of blood glucose to a level of ≤8.0 mmol/L was necessary to reduce the risk of complications after liver transplantation.
Authors: Gero Puhl; Klaus-D Schaser; Daniel Pust; Katrin Köhler; Brigitte Vollmar; Michael D Menger; Peter Neuhaus; Utz Settmacher Journal: Liver Transpl Date: 2005-05 Impact factor: 5.799
Authors: Miguel Jiménez-Pérez; Rocío González-Grande; Edith Omonte Guzmán; Víctor Amo Trillo; Juan Miguel Rodrigo López Journal: World J Gastroenterol Date: 2016-07-28 Impact factor: 5.742
Authors: Zobair Younossi; Katrin Kochems; Marc de Ridder; Desmond Curran; Eveline M Bunge; Laurence de Moerlooze Journal: Hum Vaccin Immunother Date: 2017-07-25 Impact factor: 3.452